PDCD1 and cancer: Monoclonal antibodies targeting the immune-checkpoint inhibitors (ICIs), such as programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1 or CD274), have greatly improved the prognosis of multiple tumor patients, although only 20%–40% of patients responded to this type of cancer therapy[32].